EGFR and non-small cell lung carcinoma: qRT-PCR assay unveiled higher miR-214 expression in the acquired erlotinib-resistant HCC827 (HCC827/ER) cells than in HCC827 cells and in NSCLC patients’ plasma with acquired EGFR-TKI resistance compared to those before exposure to EGFR-TKI therapy.